<?xml version="1.0" encoding="UTF-8"?>
<p id="Par44">The primary objective of this study is to describe the time to change in systemic therapy after SRT in patients with ER-positive HER2-negative advanced breast cancer receiving an AI in combination with a CDK 4/6 inhibitor who have up to 5 sites of OPD.</p>
